ESSENCE

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia

Stadium
klaar
Middel
Olezarsen
Populatie
ASCVD
Fase
III
First Patient In
23 juni 2023
Last Patient In
14 februari 2024
Last Patient Last Visit
28 mei 2025

National Lead

prof. dr. E.S.G. Stroes

Cardioloog

Studiedirecteur

drs. K.W. Wu

Cardioloog

Contact Kantoor

S. Jansen

Studiemanager

De pagina is verlopen.